%0 Journal Article
%A Capra, Marcelo
%A Martin, Thomas
%A Moreau, Philippe
%A Baker, Ross
%A Pour, Ludek
%A Min, Chang-Ki
%A Leleu, Xavier
%A Mohty, Mohamad
%A Reinoso Segura, Marta
%A Turgut, Mehmet
%A LeBlanc, Richard
%A Risse, Marie-Laure
%A Malinge, Laure
%A Schwab, Sandrine
%A Dimopoulos, Meletios
%T Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
%D 2022
%@ 0390-6078
%U http://hdl.handle.net/10668/20520
%X Renal impairment (RI) is common in patients with multiple myeloma (MM) and new therapies that can improve renal function are needed. The phase III IKEMA study (clinicaltrials gov. Identifier: NCT03275285) investigated isatuximab (Isa) with carfilzomib and dexamethasone (Kd) versus Kd in relapsed MM. This subgroup analysis examined results from patients with RI, defined as estimated glomerular filtration rate = 3 treatment-emergent adverse events was similar between the two arms (79.1% in Isa-Kd vs. 77.8% in Kd). In summary, the addition of Isa to Kd improved clinical outcomes with a manageable safety profile in patients with RI, consistent with the benefit observed in the overall IKEMA study population.
%K Low-dose dexamethasone
%K Pooled analysis
%K Open-label
%K Phase-iii
%K Lenalidomide
%K Bortezomib
%K Dialysis
%K Failure
%K Complications
%K Reversibility
%~